28th Jan 2016 07:45
LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Thursday said the US Food & Drug Administration has granted a Breakthrough Therapy designation for Lynparza for the treatment of prostate cancer.
The designation for Lynparza for this segment of patients means the US regulator will expedite the review of the test submission data for the drug within 60 days, AstraZeneca said.
"More than 27,000 men died of prostate cancer last year in the US alone. The Breakthrough Therapy designation for Lynparza is encouraging news for patients, and their families, as there are currently very limited treatment options for metastatic Castration Resistant Prostate Cancer," said Antoine Yver, the head of oncology in AstraZeneca's global medicines development team.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca